It also recommended that doctors should discontinue treatment if NAION is confirmed
Indeed, liraglutide, the first GLP- 1 RA approved for chronic weight management (in 2014) was shown in the SCALE Phase 3 trial to produce mean weight reduction from baseline to week 56, of 8.0% with liraglutide 3.0 mg versus 2.8% with placebo (last-observation-carried-forward imputationLOCF) [3]
Regular communication about symptoms, careful tracking of side effects, and proper dose management can significantly affect treatment outcomes
GLP-1 agonists often continue indefinitely for weight maintenance, while GH secretagogues may cycle with periodic breaks
Small portions eaten more frequently reduce the degree to which food accumulates and causes discomfort
The drug is expensive at about $1,300 a month and health insurance often doesnt cover anti-obesity drugs